Alpha 1-antitrypsin deficiency natural history, complications, and prognosis: Difference between revisions
(Created page with "{{Alpha 1-antitrypsin deficiency}} {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}} ==Overview== Alpha 1-antitrypsin deficiency (A1AD) may be slow to manifest in symptom onset i...") |
m (Robot: Changing Category:Disease state to Category:Disease) |
||
Line 14: | Line 14: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
Line 22: | Line 24: | ||
[[Category:Metabolic disorders]] | [[Category:Metabolic disorders]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
[[Category:Disease | [[Category:Disease]] | ||
Revision as of 18:51, 9 December 2011
Alpha 1-antitrypsin deficiency Microchapters |
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Alpha 1-antitrypsin deficiency natural history, complications, and prognosis On the Web |
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
FDA on Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
CDC on Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
Alpha 1-antitrypsin deficiency natural history, complications, and prognosis in the news |
Blogs on Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Alpha 1-antitrypsin deficiency (A1AD) may be slow to manifest in symptom onset in newborns. As a patient ages, liver dysfunction and deterioration will occur. Mortality is directly related to the respiratory failure caused by a fall in forced expiratory volume.
Natural History
- Within the first two decades of life, liver dysfunction tends to dominate the clinical picture, while lung function is generally preserved.
- Two prospective studies have followed newborns identified at birth with blood screening for up to 16 years, and both showed no difference in lung function compared with controls.
- After the first 20 years, however, lung function begins to deteriorate at the rate mentioned above.
Respiratory failure accounts for ~ 62% of deaths, and complications of chronic liver disease for ~ 13%. The mean age of death in one study was 53 years old for nonsmokers and 40 years old for smokers, with only 16% surviving to 60 years old. This compares to ~ 85% surviving to 65 years old in the general population. Mortality is directly related to FEV1 (forced expiratory volume), and rises exponentially as FEV1 falls below 35% predicted. In a Danish study, asymptomatic nonsmokers, who were identified as relatives of symptomatic patients with alpha-1 AT had a normal life expectancy. This is consistent with the presence of a subgroup of patients with severe deficiency in alpha-1 AT who escape medical attention.